Storia in 20 fonti

FDA approves landmark pancreatic cancer drug

A clinical trial saw patients on the drug live a median of 13.2 months

Raccontata da

independent.co.uk+8 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

theweek.comStai leggendo7 h fa

FDA approves landmark pancreatic cancer drug

A clinical trial saw patients on the drug live a median of 13.2 months

originale

newsbytesapp.com

Timeline cronologica

mercoledì 26 agosto 2026·forbes.com
FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque
Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
mercoledì 26 agosto 2026·biopharmadive.com
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly…

10 h fa

FDA approves pancreatic cancer drug that nearly doubles survival time

The FDA has approved daraxonrasib (Rasonque), a revolutionary drug by Revolution Medicines, which nearly doubled survival rates in pancreatic cancer clinical trials.

Leggi questa versione → originale

nbcnews.com1 g fa

FDA approves ‘game-changing’ pancreatic cancer drug

In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who got standard care.

Leggi questa versione → originale

cbsnews.com23 h fa

FDA approves new pancreatic cancer drug that could extend patients' lives

Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.

Leggi questa versione → originale

abcnews.com1 g fa

FDA approves breakthrough drug to treat advanced pancreatic cancer

The Food and Drug Administration approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer.

Leggi questa versione → originale

endpoints.news1 g fa

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA approves Revolution Medicines' daraxonrasib (Rasonque) for second-line pancreatic cancer, after it nearly doubled survival in a Phase 3 to 13.2 months vs. 6.7 months on chemo.

Leggi questa versione → originale

mercoledì 26 agosto 2026·

medpagetoday.com

'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval

RAS inhibitor daraxonrasib doubled survival outcomes in second-line trial

mercoledì 26 agosto 2026·

apnews.com

FDA approves landmark pancreatic cancer drug that's shown to improve survival

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.

mercoledì 26 agosto 2026·

statnews.com

FDA approves new pancreatic cancer drug expected to usher in new era of treatment

The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.

mercoledì 26 agosto 2026·

endpoints.news

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA approves Revolution Medicines' daraxonrasib (Rasonque) for second-line pancreatic cancer, after it nearly doubled survival in a Phase 3 to 13.2 months vs. 6.7 months on chemo.

mercoledì 26 agosto 2026·

abcnews.com

FDA approves breakthrough drug to treat advanced pancreatic cancer

The Food and Drug Administration approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer.

mercoledì 26 agosto 2026·

cnn.com

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN

The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines’ targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or…

mercoledì 26 agosto 2026·

cnbc.com

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

The drug is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.

mercoledì 26 agosto 2026·

thestar.com

FDA approves landmark pancreatic cancer drug that’s shown to improve survival

WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more…

mercoledì 26 agosto 2026·

jpost.com

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | The Jerusalem Post

The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many…

mercoledì 26 agosto 2026·

independent.co.uk

New hope for pancreatic cancer patients after FDA approves drug to improve survival

Pancreatic cancer is among the deadliest forms, largely because detection is difficult before malignancy spreads to other organs

mercoledì 26 agosto 2026·

nbcnews.com

FDA approves ‘game-changing’ pancreatic cancer drug

In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who got standard care.

mercoledì 26 agosto 2026·

qz.com

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

The drug, Rasonque, nearly doubled median overall survival compared with standard chemotherapy in a 500-patient trial

mercoledì 26 agosto 2026·

benzinga.com

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA

FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials show a 60% reduced death risk vs chemotherapy.

mercoledì 26 agosto 2026·

upi.com

FDA approves new treatment for those with advanced pancreatic cancer - UPI.com

On Wednesday, the U.S. Food and Drug Administration announced its approval of Rasonque, a new treatment option for people with pancreatic cancer.

mercoledì 26 agosto 2026·

huffpost.com

FDA Approves Landmark Pancreatic Cancer Drug That's Shown To Improve Survival

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.

mercoledì 26 agosto 2026·

washingtonexaminer.com

FDA approves breakthrough pancreatic cancer drug proven to extend survival

Former Nebraska Sen. Ben Sasse credited the drug with extending his life after his terminal cancer diagnosis.

giovedì 27 agosto 2026·

cbsnews.com

FDA approves new pancreatic cancer drug that could extend patients' lives

Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.

giovedì 27 agosto 2026·

france24.com

FDA approves new drug Rasonque to treat advanced pancreatic cancer

The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease. A large trial…

FDA approves landmark pancreatic cancer drug

Timeline cronologica

FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque

Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA

FDA approves pancreatic cancer drug that nearly doubles survival time

FDA approves ‘game-changing’ pancreatic cancer drug

FDA approves new pancreatic cancer drug that could extend patients' lives

FDA approves breakthrough drug to treat advanced pancreatic cancer

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval

FDA approves landmark pancreatic cancer drug that's shown to improve survival

FDA approves new pancreatic cancer drug expected to usher in new era of treatment

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA approves breakthrough drug to treat advanced pancreatic cancer

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

FDA approves landmark pancreatic cancer drug that’s shown to improve survival

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | The Jerusalem Post

New hope for pancreatic cancer patients after FDA approves drug to improve survival

FDA approves ‘game-changing’ pancreatic cancer drug

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA

FDA approves new treatment for those with advanced pancreatic cancer - UPI.com

FDA Approves Landmark Pancreatic Cancer Drug That's Shown To Improve Survival

FDA approves breakthrough pancreatic cancer drug proven to extend survival

FDA approves new pancreatic cancer drug that could extend patients' lives

FDA approves new drug Rasonque to treat advanced pancreatic cancer